Zobrazeno 1 - 10
of 300
pro vyhledávání: '"Shumei Kato"'
Autor:
Yuji Uehara, Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary K. Nesline, Sarabjot Pabla, Jeffrey M. Conroy, Paul DePietro, Heidi Ko, Jason K. Sicklick, Razelle Kurzrock
Publikováno v:
Cancer Communications, Vol 44, Iss 10, Pp 1168-1172 (2024)
Externí odkaz:
https://doaj.org/article/0d1f115fc5604621bd3058b976a0f2cb
Multi‐omic analysis in carcinoma of unknown primary (CUP): therapeutic impact of knowing the unknown
Autor:
Shumei Kato, Sophia Gumas, Jacob J. Adashek, Ryosuke Okamura, Suzanna Lee, Jason K. Sicklick, Razelle Kurzrock
Publikováno v:
Molecular Oncology, Vol 18, Iss 4, Pp 956-968 (2024)
Carcinoma of unknown primary (CUP) is a difficult‐to‐manage malignancy. Multi‐omic profiles and treatment outcome vs. degree of precision matching were assessed. Tumours underwent next‐generation sequencing (NGS) [tissue and/or blood‐derive
Externí odkaz:
https://doaj.org/article/2f709749a5e648c68c0ec4e1799e0aa3
Autor:
Bryan H. Louie, Shumei Kato, Jordan S. Lim, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura, Suzanna Lee, Lisa Kim, Jason K. Sicklick, Scott M. Lippman, Razelle Kurzrock
Publikováno v:
iScience, Vol 27, Iss 8, Pp 110465- (2024)
Summary: Treatment of rare/ultra-rare tumors is an unmet need due to a lack of standardized therapies and clinical trials. We developed the Molecular Tumor Board (MTB), a multidisciplinary team that integrates molecular profiling to generate personal
Externí odkaz:
https://doaj.org/article/e64d4acaf51348368671cd29fd7f4874
Autor:
Jacob J. Adashek, Chinmayi Pandya, Nicholas J. Maragakis, Pradip De, Philip R. Cohen, Shumei Kato, Razelle Kurzrock
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-13 (2024)
Abstract Background Neuregulin-1 (NRG1) is implicated in both cancer and neurologic diseases such as amyotrophic lateral sclerosis (ALS); however, to date, there has been little cross-field discussion between neurology and oncology in regard to these
Externí odkaz:
https://doaj.org/article/5510840f22664d2da2e8c1900f898037
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Although KRAS G12C inhibitors have proven that KRAS is a “druggable” target of cancer, KRAS G12C inhibitor monotherapies have demonstrated limited clinical efficacy due to primary and acquired resistance mechanisms. Multiple combinations of KRAS
Externí odkaz:
https://doaj.org/article/4077e8913381419588d33f240e743af9
Autor:
Yu Fujiwara, Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mary K. Nesline, Jeffrey M. Conroy, Paul DePietro, Sarabjot Pabla, Scott M. Lippman, Razelle Kurzrock
Publikováno v:
iScience, Vol 27, Iss 4, Pp 109632- (2024)
Summary: Indoleamine 2,3-dioxygenase 1 (IDO1), which catabolizes tryptophan, is a potential target to unlock the immunosuppressive tumor microenvironment. Correlations between IDO1 and immune checkpoint inhibitor (ICI) efficacy remain unclear. Herein
Externí odkaz:
https://doaj.org/article/9df1b09acc8f49f69d386a55f32c1121
Autor:
Aditya Shreenivas, Filip Janku, Mohamed A. Gouda, Hui-Zi Chen, Ben George, Shumei Kato, Razelle Kurzrock
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-20 (2023)
Abstract Anaplastic lymphoma kinase (ALK) alterations (activating mutations, amplifications, and fusions/rearrangements) occur in ~3.3% of cancers. ALK fusions/rearrangements are discerned in >50% of inflammatory myofibroblastic tumors (IMTs) and ana
Externí odkaz:
https://doaj.org/article/cb8bd6399dbb41f89dfe7a91e18fac6e
Autor:
Shai Rosenberg, Gil Ben Cohen, Shumei Kato, Ryosuke Okamura, Scott M. Lippman, Razelle Kurzrock
Publikováno v:
Molecular Oncology, Vol 17, Iss 9, Pp 1844-1856 (2023)
Genomic analysis, performed on tumoral tissue DNA and on circulating tumor DNA (ctDNA) from blood, is the cornerstone of precision cancer medicine. Herein, we characterized the clinical prognostic implications of the concordance of alterations in maj
Externí odkaz:
https://doaj.org/article/d082f4cb7f7c40e2bbf553988eea8236
Autor:
Hirotaka Miyashita, Razelle Kurzrock, Nicholas J. Bevins, Kartheeswaran Thangathurai, Suzanna Lee, Sarabjot Pabla, Mary Nesline, Sean T. Glenn, Jeffrey M. Conroy, Paul DePietro, Eitan Rubin, Jason K. Sicklick, Shumei Kato
Publikováno v:
npj Genomic Medicine, Vol 8, Iss 1, Pp 1-10 (2023)
Abstract Immune checkpoint blockade is effective for only a subset of cancers. Targeting T-cell priming markers (TPMs) may enhance activity, but proper application of these agents in the clinic is challenging due to immune complexity and heterogeneit
Externí odkaz:
https://doaj.org/article/9b9d07a8e8b84b69aa3ad5d3d41c13e8
Autor:
Jacob J. Adashek, Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Pradip De, Suzanna Lee, Sarabjot Pabla, Mary Nesline, Jeffrey M. Conroy, Paul DePietro, Scott Lippman, Razelle Kurzrock
Publikováno v:
Cancer Medicine, Vol 12, Iss 12, Pp 13155-13166 (2023)
Abstract Background Lymphocyte activation gene 3 (LAG‐3) or CD223 is a transmembrane protein that serves as an immune checkpoint which attenuates T‐cell activation. Many clinical trials of LAG‐3 inhibitors have had modest effects, but recent da
Externí odkaz:
https://doaj.org/article/cfe72fc33e194e9395740e5950d4b95c